Shanghai Fosun Pharmaceutical (Group) Co (HK:2196) has released an update.
Shanghai Fosun Pharmaceutical (Group) Co., Ltd has announced progress on its planned privatization of Henlius, stating that the precondition for a potential share alternative offer has been met with sufficient interest from shareholders. The company, along with Henlius and the offeror, is preparing to finalize the details of this offer, following the acquisition of necessary letters of interest from shareholders.
For further insights into HK:2196 stock, check out TipRanks’ Stock Analysis page.
